Abstract
The discovery of Helicobacter pylori has already changed the natural history of peptic ulcer disease, with most patients being cured at their first presentation. Similarly, the incidence of gastric cancer and other diseases related to H. pylori are likely to be greatly reduced in the near future. Isolation of the spiral intragastric bacterium H. pylori totally reversed the false dogma that the stomach was sterile, and it taught us that chronic infectious disease can still exist in modern society. Helicobacter pylori’s unique location, persistence, and evasion of the immune system offer important insights into the pathophysiology of the gut. Also, the fact that it was overlooked for so long encourages us to think “outside the box” when investigating other diseases with obscure etiologies. We should consider such provocative scientific ideas as bridges to the future disease control.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Background
In recent years, research groups have concentrated on the molecular structures whereby Helicobacter pylori survives in the hostile gastric environment and persists in spite of the host’s immune response. Epidemiologic studies have also provided convincing evidence that H. pylori is associated not only with gastroduodenal diseases, including chronic gastritis, peptic ulcer diseases, low-grade gastric mucosa-associated lymphoid tissue (MALT) lymphoma, and noncardiac gastric adenocarcinoma,1–6 but also with extragut diseases.7–12
The initial advance that facilitated the explosion of research related to H. pylori was the development of microaerobic cultivation methods for this bacterium. Then, it was shown that intentional infection of a volunteer led to gastritis.13 Classical bacteriology demonstrated that H. pylori is a Gram-negative, flagellated organism that produces a number of enzymes, including catalase and urease, which help neutralize host responses and favor colonization.14,15 One of the early benefits gained from this basic research was the demonstration that urease is produced by virtually all strains of H. pylori. This led to the development of accurate diagnostic tests, including the rapid urease test and the urea breath test. A stool antigen test has also emerged as an informative, noninvasive means by which to diagnose infection via detection of bacterial antigen.16 In addition, the ability to culture H. pylori provided a diagnostic test that allowed assessment of antibiotic susceptibility.
Before the modern discovery of intragastric bacteria 25 years ago,17 several reports dealt with spiral gastric bacteria as long ago as 1890. The modern discovery of H. pylori might have been delayed because in 1954, Palmer18 denied the existence of microorganisms in the human stomach, claiming that spiral bacteria were seen only post-mortem because microorganisms could not survive in the acidic gastric environment. However, microorganisms had been described in the gastric mucosa since the 1890s.19 For example, in Japan, Kasai and Kobayashi20 of the Kitasato Institute reported propagation of a spirochete-like organism, probably Helicobacter felis, from the stomach of dogs and cats, but not from laboratory animals (Fig. 1). They showed that when rabbits infected with these spirochetes were also inoculated with the virus fixe (attenuated rabies virus), marked hemorrhagic lesions occurred in the gastric mucosa.20 They also demonstrated that spirochetes inoculated into the gastric mucosa of the mouse could be eradicated by arsaminol20 (a modern equivalent of arsaminol is thought to be bismuth, a close relative of arsenic).21,22 Seventy years then elapsed before scientists again attempted to treat gastric diseases associated with “spirochetes,” that is, Helicobacter infection.
Present status
Epidemiology
Most new H. pylori infections occur in children; however, in the absence of specific clinical signs associated with infection, the mode of transmission is difficult to define. Vomitus, saliva, and feces are the presumed sources of direct transmission, particularly in crowded housing conditions. Generally, infection correlates inversely with socioeconomic conditions,23 with lifetime infection rates in affluent countries dropping toward 10%, while rates in countries with emerging economies approach 80%–90%.16,24,25 Most infected individuals experience asymptomatic gastritis, although recurrent gastroduodenal ulceration may occur in 10%–15% of the infected population. The incidence of gastric cancer is lower, with approximately 1%–5% of infected individuals developing adenocarcinoma and even fewer experiencing gastric MALT lymphoma.1,2,26–29
Initially H. pylori depends on its urease enzyme to survive in an acid environment, and then on its spiral shape and motility to reach the gastric epithelium, where it sticks to cells through the various specific adhesion molecules. Once attached, most organisms then deliver damaging toxins to the mucosa.
Pathogenesis
The most investigated of these toxins stem from a segment of bacterial DNA referred to as the cag pathogenicity island (cag PAI). The presence of the cag PAI is usually associated with presence of the s1m1 (more harmful) subtype of the vacuolating cytotoxin VacA. Genes within the cag PAI encode proteins such as CagE, an ATPase that drives a type IV secretion apparatus that allows bacterial macromolecules, especially CagA toxin, to translocate into the host cell.3,30 The intact cag PAI of H. pylori plays a significant role in the pathogenesis of gastritis in humans, since H. pylori carrying the cag PAI is associated with increased chemokine expression in gastric mucosal specimens31 and stronger inflammation.
CagA is injected into epithelial cells by the type IV secretory system, possibly as a mechanism to reduce the stress of gastric acid on the bacterium, since its transcription is increased at low pH.32 VacA is a pore-forming protein, which causes epithelial cells to vacuolate in vitro. Retrospective analyses of samples from gastric cancer patients have suggested an association with the cagA +/vacA +-positive genotype.33 Further studies have confirmed that a risk for both cancer and peptic ulcer is associated particularly with the cagA/vacA s1m1 genotype, but rarely with strains carrying the vacA s2m2 polymorphism.34,35 However, the cagA gene does not act alone, because delivery of the CagA protein into epithelial cells appears to be dependent on a secretion system encoded for by the adjacent cluster of genes, the cag PAI.36 After the CagA protein is injected into the host cell cytoplasm, it is tyrosine phosphorylated by host Src kinases and subsequently changes the epithelial morphology.37–41 CagA in strains from distinct geographic populations appears to be phosphorylated to a different degree, resulting in graded effects on intracellular signaling.42,43
Oxygen-derived free radicals, which are released from activated neutrophils, are considered to be one of the potential toxic factors involving H. pylori-induced gastric mucosal injury, since H. pylori exhibits chemotactic activity for neutrophils.44,45 Neutrophil infiltration of the gastric mucosa leads to development of the initial lesion in H. pylori-associated gastritis and remains a hallmark of active bacterial infection. In response to the activation of neutrophils, NADPH oxidase (Nox) in the neutrophils’ cell membranes becomes activated; an electron transfer takes place from NADPH in cells to oxygen inside and outside of cells, and the oxygen molecules that receive an electron become superoxide radicals (O2 −), which are rapidly converted to hydrogen per oxides (H2O2) by spontaneous dismutation, or to enzymatic superoxide dismutase (SOD) and hydroxyl radicals (•OH), which are formed nonenzymatically in the presence of Fe2+. In neutrophils, myeloperoxidase (MPO) also results in the formation of a potent oxidant, the hypochlorous anion (OCl−), from H2O2 in the presence of Cl−. This hypochlorous anion reacts with ammonia, derived from urea by H. pylori-associated urease, and yields cytotoxic oxidant, monochloramine (NH2Cl) 46 with its lipophilic property, allowing it to freely penetrate biological membranes to oxidize intracellular components47 (Fig. 2).
8-Hydroxy-2-deoxyguanosine (8-OHdG) is one of the most abundant lesions in DNA induced by reactive oxygen species.48 It results from an attack by a singlet hydroxyl or oxygen radical on guanine (Fig. 2). Patients with cagA-positive H. pylori strains have higher 8-OHdG levels than both cagA-negative and H. pylori-negative patients.49 The cagA-positive patients are characterized by greater oxidative DNA damage overall and at a younger age, in the presence of multifocal atrophy.49
The preferred animal model for studying H. pylori gastritis is the Mongolian gerbil (Meriones unguiculatus).50–53 In one study, gerbils infected with a mutated strain lacking cagE exhibited a substantially reduced severity of gastritis.54 Gastric ulceration developed in all of the gerbils infected with the wild-type strain but in none of those infected with the cagE mutant strain. In addition, intestinal metaplasia and gastric cancer developed in some gerbils with wild-type infection but not in animals infected with the cagE-negative mutant.54 These findings were confirmed by showing that the repaired cagE-positive H. pylori strain induced severe gastric inflammation, gastric mucosal atrophy, and gastric ulcer formation.55 Recently, the nucleotide sequences of cDNAs encoding preproghrelin, a precursor of ghrelin (an appetite-promoting endocrine peptide produced mainly from A-like cells in the gastric fundus)52,56 and sonic hedgehog, a morphogen that may regulate and organize fundic gland epithelial differentiation, have been identified in the Mongolian gerbil.53,57 Preproghrelin and sonic hedgehog mRNA expression is significantly reduced in the gastric mucosa of Mongolian gerbils with persistent H. pylori colonization.52,53
After reaching the mucosa and attaching by means of its lectins, H. pylori applies toxin to the gastric mucosa (Fig. 3). Then, the cells change their morphology and migrate, some detach, and sometimes apoptosis occurs. The healing process involves proliferation of adjacent, more healthy cells. Gastric epithelial cell turnover is regulated by the balance between cell death (apoptosis) and cell proliferation (Fig. 3). Such a regulated cell turnover by apoptosis and proliferation is essential for maintaining healthy gastric mucosal integrity. Some cells differentiate into intestinal tissue, a transformation called intestinal metaplasia. This may be somewhat protective in that H. pylori is unable to attach to these cells, allowing inflammatory processes to become quiet in these areas. However, extensive metaplasia is associated with decreased acid secretion, which may allow other commensal bacteria to colonize and carcinogen formation to occur. Proliferation by itself is not carcinogenic, but mutagens, such as monochloramine, may be formed in the presence of ammonia and hypochlorous anion. These cause errors in transcription to occur.
At an earlier phase after bacterial inoculation, an initial transient enhancement of cell apoptosis (2–4 weeks) and a later increase in cell proliferation (16–20 weeks) occur in the H. pylori-colonized gastric mucosa of gerbils.58 While the level of apoptosis increases as H. pylori-evoked gastric mucosal inflammation advances in mice, the enhanced level of apoptosis is significantly attenuated in H. pylori-colonized gastric mucosa of gerbils with enhanced inflammation and epithelial proliferation in the gastric mucosa during longer term colonization,59 suggesting a possible link between attenuated gastric mucosal apoptosis and a specific carcinogenesis in gerbils after H. pylori colonization.60,61
Peptic ulcer disease
The strongest association of H. pylori infection is with peptic ulcer disease;62 95% of duodenal ulcers and 70% of gastric ulcers are related to H. pylori infection. Several cohort studies have estimated that the lifetime risk of ulcer disease in H. pylori-positive subjects is three to ten times that in H. pylori-negative subjects.63 Introduction of H. pylori eradication regimens has completed the evidence for a causal relation between H. pylori and peptic ulcer disease because H. pylori eradication has been shown to strongly reduce the risk of ulcer recurrence.64 In prospective controlled studies of duodenal ulcer recurrence, ulcers recurred in 55%–86% of patients in H. pylori-positive cohorts, in contrast to a rate of 3%–21% in H. pylori-negative (successfully eradicated) cohorts65–70 (Table 1). Gastric ulcers typically recurred in 46%–71% of patients in H. pylori-positive cohorts, contrasting with ulcer recurrence rates of 10% or less in H. pylori-negative (successfully eradicated) cohorts71–76 (Table 2).
The meta-analytic results of a North American study by Laine et al.70 have shown that H. pylori eradication markedly decreases ulcer recurrence. Nevertheless, ulcers recurred in 20% of patients in these studies within 6 months, despite a successful cure of infection and no reported use of nonsteroidal anti-inflammatory drugs (NSAIDs), suggesting that non-H. pylori, non-NSAID ulcers may be more common in the United States than previously believed.
According to a recent systematic review of 56 randomized controlled trials of treatment for peptic ulcer disease in H. pylori-positive adults,77 a 1 to 2 weeks’ course of H. pylori eradication therapy is an effective treatment. Namely, in duodenal ulcer (DU) healing, eradication therapy was superior to several weeks of ulcer healing drugs [34 trials, 3910 patients, relative risk (RR) of ulcer persisting = 0.66] or no treatment (2 trials, 207 patients, RR = 0.37). In gastric ulcer (GU) healing, no significant differences were detected between eradication therapy and administration of an ulcer healing drug (14 trials, 1572 patients, RR = 1.25). For preventing DU recurrence, no significant differences were detected between eradication therapy and maintenance therapy with an ulcer healing drug (4 trials, 319 patients, RR = 0.73), but eradication therapy was superior to no treatment (27 trials, 2509 patients, RR = 0.20). For preventing GU recurrence, eradication therapy was superior to no treatment (11 trials, 1104 patients, RR = 0.29).
The incidence of peptic ulcers has steadily decreased in Western countries in the last two decades. The decreasing prevalence of peptic ulcers is thought to result both from contraction of the formerly large pool of patients with recurrent ulcer disease by H. pylori eradication at first presentation and from the decreasing prevalence of H. pylori infection in the population.24,78,79 The latter is related to several factors, such as improved hygiene and living conditions, decreased family sizes, and the use of antimicrobial therapy for other purposes.
Helicobacter pylori and NSAIDs are the two major causes of peptic ulcer disease. Their potential interaction in the induction of ulcer disease remains controversial. A thorough analysis of interaction data has revealed that the ulcer-inducing effects of both risk factors are cumulative.80 Eradication of H. pylori in chronic NSAID users does no harm, and in some studies has decreased the incidence of ulcer disease. In a study from Hong Kong, patients starting with NSAID maintenance therapy were randomized to eradication therapy or placebo. After 6 months of follow-up, the incidence of ulcers was 12.1% in the eradication group and 34.4% in the placebo group (P = 0.0085). The corresponding probabilities of complicated ulcers after 6 months were 4.2% and 27.1% (P = 0.0026), respectively.81 These data show that, at least in an Asian population, screening and treatment for H. pylori infection significantly reduces the risk of ulcers in patients starting long-term NSAID treatment, but also that eradication alone is insufficient to totally prevent ulcers and ulcer complications. In several studies, H. pylori eradication was inferior to omeprazole maintenance treatment for prevention of recurrent NSAID-associated ulcer bleeding.82,83 An overall synthesis of these data suggests that NSAIDs and H. pylori are independent, but not necessarily additive, causes of peptic ulcer. The wise choice might be to address both issues in all patients with ulcer complications: supplement NSAID users at risk with a second agent, consider the option of selective cyclooxygenase-2 (cox-2) inhibitors, and eradicate H. pylori as well.
Functional dyspepsia
Recently, the “Rome III” classification for functional gastrointestinal disorders was defined.84 In this classification, functional dyspepsia (FD) is included in the subcategory of functional gastroduodenal disorders.85 Four types of functional gastroduodenal disorders are distinguished: FD [B1, comprising postprandial distress syndrome (B1a) and epigastric pain syndrome (B1b)]; belching disorders (B2); functional nausea and vomiting disorders, functional vomiting, and cyclic vomiting syndrome (B3); and rumination syndrome (B4).85,86
Of patients with functional dyspepsia, 30%–60% carry H. pylori, but this prevalence is not much different from that in the unaffected population.87 Various studies have focused on the effect of H. pylori eradication in patients with both functional and uninvestigated dyspepsia. A meta-analysis of 13 randomized studies of nonulcer dyspepsia showed that when dyspepsia outcomes are dichotomized into minimal/resolved versus same/worse symptoms, H. pylori eradication is associated with an 8% RR reduction compared with placebo.88 The calculated number-needed-to-treat to cure one case of dyspepsia is 18. Apart from the focus on cure of symptoms, cost efficiency is also an issue when treating large groups of patients. Given this reported number-needed-to-treat, it remains unclear whether H. pylori eradication is a cost-effective strategy. In a Canadian primary care study, however, H. pylori eradication was reported to be more cost-effective after 1 year of follow-up than empirical diagnosis and treatment.89,90 In another interesting study, Sonnenberg and Townsend91 found that, for some reason, expenditure on many other aspects of health care decreased after patients had eradicated H. pylori.
Another Cochrane meta-analysis compared treatment strategies for uninvestigated dyspepsia.92 Individual strategies consisted of initial pharmacological therapy (with endoscopy for treatment failures), early endoscopy, testing for H. pylori and endoscopy only for those testing positive, or H. pylori eradication therapy with or without prior testing. The analysis showed that proton-pump inhibitors (PPIs) are effective in the treatment of dyspepsia. Early investigation by endoscopy or H. pylori testing benefited some patients with dyspepsia but was not cost-effective as part of an overall management strategy.92 A meta-analysis of five studies comparing prompt endoscopy followed by targeted treatment versus an H. pylori test-and-treat strategy without further investigation reported that endoscopy was associated with a small symptom benefit at 1 year (RR, 0.95), but this strategy was not cost-effective.93 In summary, H. pylori play a role in the etiology of dyspeptic symptoms; thus, H. pylori test-and-treat strategies are effective for a subgroup of patients with dyspepsia. For patients with uninvestigated dyspepsia, an H. pylori test-and-treat strategy is an appropriate option, although empirical acid-suppressive therapy can be more efficient in populations with a low H. pylori prevalence. Also, in patients with investigated FD, H. pylori eradication is a relevant option. In both situations, patients must be aware that symptom resolution may take months after completion of therapy.
Atrophic gastritis, intestinal metaplasia, and gastric cancer
Thirty years ago, Correa et al.94 proposed that gastritis could progress to gastric cancer, which made the identification of H. pylori as a major cause of gastritis even more relevant. Chronic H. pylori-induced inflammation can eventually lead to loss of the normal gastric mucosal architecture, with destruction of gastric glands and replacement by intestinal metaplasia. This process of atrophic gastritis and intestinal metaplasia occurs in approximately half of the H. pylori-colonized population, first in those subjects and at those sites where inflammation is most severe.95 Because not everyone infected with H. pylori develops gastric cancer, several modifiers have been identified. Currently, the perception is that gastric cancer arises from multiple “hits,” which include oxidative stress and environmental toxins, which increase mutation rates. Diet, bacterial factors, and genes regulating the host response likely affect the degree of oxidative stress and DNA damage.96 Host polymorphisms in the regions controlling interleukin (IL)-1 have been reported to be associated with an increased incidence of hypochlorhydria and gastric cancer,97–102 probably because these regions regulate the inflammatory response to bacterial infections. Areas of gland loss and intestinal metaplasia extend with time multifocally, and although they do not give rise to any specific symptoms, they increase the risk for gastric cancer by five-to 90-fold, depending on the extent and severity of atrophy.103
Evidence that H. pylori increases the risk of gastric cancer development via the sequence of metaplasia and atrophy originates from various studies that showed that H. pylori-positive subjects develop these conditions far more often than do uninfected controls.104 This finding is supported by data that show geographical associations between the prevalence of H. pylori and the incidence of gastric cancer.105,106 On the basis of these findings, it has been estimated that H. pylori colonization increases the risk of gastric cancer approximately tenfold, and H. pylori has been designated a class I carcinogen by WHO.107 Later case-control studies that looked more extensively into signs of previous H. pylori infection in gastric cancer patients and controls re ported even higher odds ratios, up to 68, for development of distal gastric cancer in the presence of H. pylori infection.108 This result is supported by data from animal models, most notably the Mongolian gerbil model, in which H. pylori infection induces atrophic gastritis and gastric dysplasia.60,61,109 The risk of development of atrophy and cancer in the presence of H. pylori is again related to host and bacterial factors, which influence the severity of the chronic inflammatory response and the amount of gastric mucosa involved. As such, the risk is increased not only in subjects colonized with cagA-positive strains110,111 but also in those with a genetic predisposition to higher IL-1 production in response to colonization.97 In the developed world, 60% to 80% of gastric cancers are therefore related to the long-term presence of H. pylori.
Interestingly, the incidence of gastric cancer has significantly decreased over the past decades in Western countries. This decrease preceded the aforementioned decrease in the prevalence of H. pylori. As a slow process over decades, however, this decrease is not relevant to an individual subject who is H. pylori-positive. Furthermore, in spite of the decline in gastric cancer incidence in Western countries, gastric cancer is still the fourth most common cancer in the world, as its incidence remains very high in large areas of the world, particularly in parts of East Asia and South America.112 Much research now focuses on the cancer-preventive effect of H. pylori eradication, aimed at both the general population and patients with preneoplastic conditions, particularly atrophic gastritis and intestinal metaplasia. In the case of the latter, several placebo-controlled randomized studies have now reported that H. pylori eradication can induce to some extent regression of atrophy.113–117 The effect of these interventions on gastric cancer prevention is, however, less obvious than the historical cancer incidence might suggest. In several studies, H. pylori eradication had in the first years of follow-up no significant effect on gastric cancer incidence.114,116,118 In all of these studies, the difference between the eradication and placebo groups with respect to the incidence of gastric cancer in the first 4 to 12 years after treatment was not significant. The striking observation in all of these studies, however, was that those gastric cancers that occurred after eradication treatment were confined to those subjects who already had atrophic gastritis and intestinal metaplasia at baseline, suggesting that the major cancer-preventive effect of H. pylori eradication is to be expected in subjects without those precancerous conditions; patients with those conditions may at least in part have already passed the point of no return. If confirmed by other studies, this result means that the observed regression of the severity of atrophy is of no direct relevance with respect to cancer risk. One study differed from the others in that it did observe a significant preventive effect of H. pylori eradication on gastric cancer development.119 The investigators monitored 1120 patients in a nonrandomized study for a mean of 3.4 years (range, 1–8 years) after H. pylori eradication treatment. Gastric cancer developed in 8 of 944 patients cured of infection and in 4 of 176 who had persistent infection (P = 0.04). The remarkable observation was that gastric cancers occurred only in patients with previous gastric ulcers and not in those who had duodenal ulcers (P = 0.005).119 This result is consistent with the hypothesis that gastric ulcer patients, in contrast to duodenal ulcer patients, are characterized by reduced gastric acid secretion, corpus-predominant gastritis, and accelerated progression toward atrophic gastritis and intestinal metaplasia. Similarly, previous studies have also shown that gastric ulcer patients are at higher risk for gastric cancer than are duodenal ulcer patients.26 The above-mentioned preventive studies, taken together, described cancer development in 29 (1.5%) of 1896 subjects receiving placebo and in 25 (0.9%) of 2754 subjects receiving eradication treatment, corresponding to an odds ratio of 0.54 for cancer development after H. pylori eradication compared with placebo, suggesting that H. pylori eradication may decrease the risk for development of distal gastric cancer. Further studies are being performed in this field, the results of which will allow a more precise determination of the cancer-preventive effect of H. pylori eradication, of whether atrophy and metaplasia are conditions beyond the point of no return, and of the side effects and costs of such preventive measures.
The Japan Collaborative Cohort Study Group for Evaluation of Cancer Risk reported that women with a family history of gastric cancer and H. pylori infection were associated with a 5.1-fold greater risk for gastric cancer compared with women without a family history of gastric cancer and who did not have H. pylori infection.120 In contrast, family history and H. pylori infection were not found to be significant risk factors for gastric cancer in male patients in their report, where the investigation of H. pylori infection was performed only by using H. pylori antibodies. Recently, results of a large nested case-control study within a prospective cohort have been reported in Japan.121 Among 123 576 subjects that were followed up from 1990 to 2004, 511 gastric cancer cases matched to 511 controls were used in this analysis. The adjusted odds ratio of gastric cancer associated with H. pylori infection was 5.1. In addition, if anti-CagA positivity was used as an indicator of previous or current infection, the risk was reached 12.5.
Gastric MALT lymphoma
Nearly all MALT lymphoma patients are H. pylori positive,122 and H. pylori-positive subjects have a significantly increased risk for the development of gastric MALT lymphoma.123 Because of diagnostic controversies and the relative rarity of this disorder, the exact incidence in H. pylori-positive subjects is unknown, but MALT lymphomas occur in fewer than 0.1% of H. pylori-positive subjects.124 Randomized trials to determine the effect of H. pylori eradication in MALT lymphoma patients are therefore not feasible, but various case series have reported that eradication can lead to complete remission in patients with low-grade gastric MALT lymphoma.125–128 Overall, approximately 60%–80% of these patients reach complete remission following H. pylori eradication, some 10% continue to have signs of minimal residual disease, and the remainder show no response or disease progression. The variation in response among different series may be due in part to different criteria for the diagnosis of MALT lymphoma, potentially including some patients with benign lymphoid aggregates. Of those who initially reach complete remission after H. pylori eradication, 10%–35% show recurrent disease during further follow-up. For that reason, long-term follow-up of MALT lymphoma patients is mandatory.129 A major predictor of the response appears to be the presence of a t(11;18) (q21;q21) translocation. This translocation is associated with API2-MALT1 fusion, the former being involved in regulation of apoptosis and the latter resembling a caspase-like protein, with an as yet unknown biological function. Together, the fusion leads to suppression of apoptosis. Several studies have reported that MALT lymphomas with this translocation respond only rarely or not at all to H. pylori eradication.130,131
Gastroesophageal reflux disease
Gastroesophageal reflux disease (GERD) has long been considered to occur independently of H. pylori colonization; that is, it occurs with the same frequency and severity in H. pylori-positive and -negative subjects. This opinion is based on cross-sectional observations that suggest that the prevalence of H. pylori among GERD patients is similar to that among controls.132 However, further studies have suggested that H. pylori might protect against the development of GERD and by that means might be of benefit to its hosts. This slowly emerging concept derives from repeated observations of a low prevalence of H. pylori among GERD patients, particularly of the more virulent strains;133 reciprocal time and geographical trends for H. pylori prevalence compared with the incidence of GERD and its complications; a potentially increased incidence of GERD after H. pylori eradication;134 and the recognition that H. pylori-induced corpus gastritis reduces acid secretion. However, no evidence suggests that H. pylori eradication has a considerable impact on either the new development of GERD,135 the worsening of preexisting GERD when treatment has been withdrawn during disease remission,136 or preexistent GERD in remission during PPI maintenance therapy.113,117 Together, these data show that although epidemiologic data suggest that there may be an inverse relation between H. pylori and GERD, the risk for new development or worsening of preexistent GERD is not an issue when deciding whether to treat H. pylori.
Diagnosis of H. pylori infection
Diagnostic methods for H. pylori infection are categorized as invasive or noninvasive tests.137 Invasive tests involve endoscopic biopsy of gastric mucosal samples, whereas noninvasive tests do not require an endoscopic procedure. The invasive tests are histology,138 rapid urease test (RUT),139 and microaerobic bacterial culture.17 The advantage of the RUT is that it is inexpensive, easy-to-use, and rapid. The advantages of culture are its specificity of 100% (direct demonstration of the presence of H. pylori) and that it allows further characterization of the organism (determining its sensitivity to antibiotics, investigating its virulence factors, etc). Noninvasive tests are the urea breath test,140 antibody tests of sera141–143 or of urine,144,145 and the H. pylori stool antigen test.146–149
H. pylori eradication therapy
During the 20 years since the World Gastroenterology Organization (WGO-OMGE) consensus conference, international or domestic consensus conferences for H. pylori eradication have been held all over the world, including in Europe, America, and Asia (Fig. 4). Most recently, on 22 November 2006, the Japanese Society for Helicobacter Research held a “Current Consensus—2006” (Management of H. pylori infection in Japan) meeting in Tokyo. In this consensus meeting, one of the main topics was whether Japan will become the first H. pylori-free country.
Originally, in 1988, Marshall et al.66 reported that H. pylori had been eradicated in 27% of a colloidal bismuth substrate (CBS)/placebo group and in 70% of a CBS/tinidazole group. Furthermore, when H. pylori persisted, 61% of duodenal ulcers healed and 84% relapsed, whereas when H. pylori was cleared, 92% of ulcers healed and only 21% relapsed during the 12-month follow-up period.66
According to a randomized, double-blind, placebo-controlled study performed by Lind et al.,150 787 patients with proven duodenal ulcer disease were randomized to treatment twice daily for 1 week with omeprazole, 20 mg (O), plus either placebo (P) or combinations of two of the following antimicrobials: amoxicillin, 1 g (A), clarithromycin, 250 or 500 mg (C250, C500), or metronidazole, 400 mg (M). Their eradication rates for the all-patients-treated analysis were 96%, OAC500; 95%, OMC250; 90%, OMC500; 84%, OAC250; 79%, OAM; and 1%, OP. These results suggest that omeprazole-based triple therapies given twice daily for 1 week produce high eradication rates, are well-tolerated, and are associated with high patient compliance.
In terms of second-line treatment, Matsuhisa et al.151 examined the eradication rate of a PPI, amoxicillin, and metronidazole (PPI/AM) regimen in 228 patients with H. pylori infection, in whom the first-line therapy with a PPI, amoxicillin, and clarithromycin administered for 1 week had failed. Their eradication rates for PPI/AM(500) and PPI/AM(750) were 90.6% and 88.6%, respectively, suggesting that PPI/AM administered for 1 week may be a highly effective second-line regimen.
In terms of third-line regimens, Gisbert et al.152 performed a third eradication treatment with levofloxacin (500 mg), amoxicillin (1 g), and omeprazole (20 mg), each twice daily for 10 days (n = 100), which resulted in per-protocol and intention-to-treat eradication rates of 66% and 60%. Although such fluoroquinolone-based rescue therapy constitutes an encouraging empirical third-line strategy after multiple previous H. pylori eradication failures,152 a high resistance rate (47.9%) to fluoroquinolone has been observed in H. pylori strains from Japanese patients after unsuccessful H. pylori eradication. Therefore, the choice of this antibiotic for the third-line treatment should be made only after drug susceptibility testing.153,154
Side effects and contraindications for H. pylori eradication
Side effects of H. pylori eradication are reported in up to 50% of patients taking the triple agent regimen.155,156 The adverse effects are usually mild; fewer than 10% of patients stop treatment due to side effects.155 The common side effects are dysgeusia and diarrhea. Amoxicillin can cause diarrhea or an allergic reaction with skin rash. Clarithromycin can cause dysgeusia, vomiting, nausea, abdominal pain, and rarely QT prolongation. Metronidazole can cause seizures, peripheral neuropathy, and a disulfiram-like reaction with ethanol, and it can increase the toxicity of anticoagulants, lithium, and phenytoin. Acute gastrointestinal mucosal lesions have been demonstrated to be an adverse event after eradication therapy. Acute duodenal erosions were observed in 13.5% of patients who received eradication therapy;157 erosions were transient and asymptomatic in the early phase after eradication. Acute gastric erosions showed the same clinical characteristics, but acute gastric ulcers with severe symptoms rarely occurred. The acute mucosal lesions that occurred were probably attributable to an increase in acid secretion associated with the resolution of gastric mucosal inflammation.6 On the other hand, the occurrence of mild reflux esophagitis at a late phase after eradication is controversial. Helicobacter pylori infection is an environmental factor that has declined as GERD has increased.158 However, a systematic review159 of randomized trials did not show any role of H. pylori eradication in causing GERD. There was no increase in reflux symptoms in almost 3000 patients with H. pylori infection who were randomly assigned eradication therapy compared with placebo.160,161
Contraindications for H. pylori eradication are documented hypersensitivity to the eradication drugs, especially penicillin-allergy. However, alternative regimens such as bismuth/tetracycline/metronidazole combinations can be used and exhibit high cure rates.
Future prospects
Interaction between gastric stem cells and H. pylori
Cells of the gastric mucosa undergo constant renewal, the rate depending on the health of the tissue. The current evidence162 suggests that a single stem cell in every gastric gland indirectly gives rise to a clone of differentiated cells, by production of committed progenitor cells. It is most likely that this stem cell occupies a niche in the isthmus composed of mesenchymal cells and extracellular matrices. This environment regulates the function of the epithelial stem cell via mesenchymal-epithelial cross talk. Recent studies in gnotobiotic mouse models of chronic atrophic gastritis163 have shown that parietal cell loss results in amplification of multi- and oligopotential gastric stem cells, which express sialylated glycan receptors recognized by H. pylori adhesions, SabA,164 HpaA,165 and HP0721.166 DNA microarray studies indicate that 6%–7% of H. pylori genes are differentially expressed in response to a shift in pH from 7 to 5.167 A large group of genes downregulated at pH 5, in particular, encode outer membrane proteins, including Hop family members that are predicted to be outer membrane porins and adhesins. Loss of acid-producing parietal cells increases bacterial adhesin expression and increases the proportion of stem cells with adhesin receptors.168 Another very provocative study suggests that in the mouse model of gastric cancer evoked with Helicobacter felis (cat Helicobacter), infection arises because malignant stem cells emerge from a pool of bone marrow cells that are recruited into areas of chronic gastritis.169
Other diseases of interest possibly influenced by H. pylori170
Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disease that leads to thrombocytopenia as a result of increased thrombocytolysis due to the appearance of autoantibodies to platelets. The acute type frequently occurs in children, often preceded by a viral infection. It develops rapidly and shows spontaneous remission. Chronic-type ITP occurs most commonly in adults and reportedly correlates with H. pylori infection. In 1988, Gasbarrini et al.7 reported that H. pylori eradication therapy to eight patients with H. pylori-positive ITP improved thrombocytosis after the therapy. Veneri et al.,171 who administered H. pylori eradication therapy to 43 patients with H. pylori-positive ITP, reported the therapy to be successful in 41 of the 43 and recognized continuous improvement in 20 (48.8%) of these 41 patients on long-term observation. According to another report by the same authors,172 the frequencies of HLA-DRB 111, HLA-DRB 114, and HLA-DQB 103 as host factors were high in H. pylori-positive ITP, while the frequency of HLA-DRB 103 as a host factor was higher in the H. pylori-negative ITP group than in the H. pylori-positive ITP group, and HLA-DQB 103 showed favorable platelet reactivity after eradication therapy in H. pylori-positive ITP.172 Inaba et al.173 administered H. pylori eradication therapy to 35 patients with chronic ITP (25 H. pylori-positive ITP patients and 10 H. pylori-negative ITP patients), and succeeded in eradicating the bacteria in all of the patients with H. pylori-positive ITP. They reported that the platelet count was improved in 11 (44%) of the 25 patients, while the platelet count was unchanged in the 10 H. pylori-negative ITP patients. We also administered bacterial eradication therapy to 37 patients with chronic ITP (26 H. pylori-positive ITP and 11 H. pylori-negative ITP patients) and succeeded in eradicating the bacteria in all of the H. pylori-positive ITP patients; we found the platelet count to be improved in 16 (62%) of the 26 patients with H. pylori-positive ITP, while the platelet count was unchanged in the 11 patients with H. pylori-negative ITP.12 In other words, there was no improvement with bacterial eradication in H. pylori-negative ITP, and the effects of the antibacterial agent itself in terms of increasing the platelet count was negligible.
Many other reports show a relation between H. pylori infection and human diseases such as iron-deficiency anemia8,174–181 and chronic urticaria.182–184
Final Message
While substantial progress has been made in our understanding of the role of genetic and environmental factors in the etiology of H. pylori-associated disease, there is still much to be learned about the epidemiology and pathogenesis of H. pylori. Although much knowledge of the potential association of H. pylori infection with human diseases has been accumulated, much of it is rather anecdotal or uncontrolled, and studies have not been consistently replicated in other centers. It is certainly true that further evidence-based studies should be performed to confirm H. pylori associations and the beneficial effects of eradication. On the other hand, eradication of H. pylori is rather simple these days and may be of no consequence in the treatment of patients with severe chronic diseases. In countries such as Japan where dreaded diseases such as gastric cancer seem to stem from H. pylori, the twenty-first century may be the time to totally eradicate this troublesome organism from the entire population.
References
N Uemura S Okamoto S Yamamoto N Matsumura S Yamaguchi M Yamakido et al. (2001) ArticleTitleHelicobacter pylori infection and the development of gastric cancer N Engl J Med 345 784–9 10.1056/NEJMoa001999 Occurrence Handle1:STN:280:DC%2BD3MrgslCqtA%3D%3D Occurrence Handle11556297
P Correa (2003) ArticleTitleBacterial infections as a cause of cancer J Natl Cancer Inst 95 E3 Occurrence Handle12671026 Occurrence Handle10.1093/jnci/95.7.E3
MJ Blaser JC Atherton (2004) ArticleTitleHelicobacter pylori persistence: biology and disease J Clin Invest 113 321–33 10.1172/JCI200420925 Occurrence Handle1:CAS:528:DC%2BD2cXhtFSlsr0%3D Occurrence Handle14755326
J Parsonnet D Forman (2004) ArticleTitleHelicobacter pylori infection and gastric cancer—for want of more outcomes JAMA 291 244–5 10.1001/jama.291.2.244 Occurrence Handle1:CAS:528:DC%2BD2cXkvVCltg%3D%3D Occurrence Handle14722152
H Suzuki S Miura M Suzuki S Terada M Nakamura M Tsuchiya (1994) ArticleTitleGastric mucosal injury: microcirculation and Helicobacter pylori Keio J Med 43 1–8 Occurrence Handle1:STN:280:DyaK2c3ks12jug%3D%3D Occurrence Handle8189675
H Suzuki T Masaoka S Nomura Y Hoshino K Kurabayashi Y Minegishi et al. (2003) ArticleTitleCurrent consensus on the diagnosis and treatment of H. pylori-associated gastroduodenal disease Keio J Med 52 163–73 Occurrence Handle14529149
A Gasbarrini F Franceschi R Tartaglione R Landolfi P Pola G Gasbarrini (1998) ArticleTitleRegression of autoimmune thrombocytopenia after eradication of Helicobacter pylori Lancet 352 878 10.1016/S0140-6736(05)60004-9 Occurrence Handle1:STN:280:DyaK1cvhtl2itw%3D%3D Occurrence Handle9742983
A Barabino C Dufour CE Marino F Claudiani A Alessandri ParticleDe (1999) ArticleTitleUnexplained refractory iron-deficiency anemia associated with Helicobacter pylori gastric infection in children: further clinical evidence J Pediatr Gastroenterol Nutr 28 116–9 10.1097/00005176-199901000-00027 Occurrence Handle1:STN:280:DyaK1M7gsFCruw%3D%3D Occurrence Handle9890483
J Kountouras G Deretzi C Zavos P Karatzoglou L Touloumis T Nicolaides et al. (2005) ArticleTitleAssociation between Helicobacter pylori infection and acute inflammatory demyelinating polyradiculoneuropathy Eur J Neurol 12 139–43 10.1111/j.1468-1331.2004.00977.x Occurrence Handle1:STN:280:DC%2BD2M%2Flt1Kmuw%3D%3D Occurrence Handle15679702
V Pasceri G Patti G Cammarota C Pristipino G Richichi G Di Sciascio (2006) ArticleTitleVirulent strains of Helicobacter pylori and vascular diseases: a meta-analysis Am Heart J 151 1215–22 10.1016/j.ahj.2005.06.041 Occurrence Handle1:CAS:528:DC%2BD28XlsFOis7Y%3D Occurrence Handle16781222
J Kountouras M Tsolaki E Gavalas M Boziki C Zavos P Karatzoglou et al. (2006) ArticleTitleRelationship between Helicobacter pylori infection and Alzheimer disease Neurology 66 938–40 10.1212/01.wnl.0000203644.68059.5f Occurrence Handle1:STN:280:DC%2BD287nsVCjsg%3D%3D Occurrence Handle16567719
A Asahi M Kuwana H Suzuki T Hibi Y Kawakami Y Ikeda (2006) ArticleTitleEffects of a Helicobacter pylori eradication regimen on anti-platelet autoantibody response in infected and uninfected patients with idiopathic thrombocytopenic purpura Haematologica 91 1436–7 Occurrence Handle1:CAS:528:DC%2BD28XhtF2gsrzE Occurrence Handle16963398
BJ Marshall JA Armstrong DB McGechie RJ Glancy (1985) ArticleTitleAttempt to fulfil Koch’s postulates for pyloric Campylobacter Med J Aust 142 436–9 Occurrence Handle1:STN:280:DyaL2M7mtlWntQ%3D%3D Occurrence Handle3982345
H Kavermann BP Burns K Angermuller S Odenbreit W Fischer K Melchers et al. (2003) ArticleTitleIdentification and characterization of Helicobacter pylori genes essential for gastric colonization J Exp Med 197 813–22 10.1084/jem.20021531 Occurrence Handle1:CAS:528:DC%2BD3sXivFaisLs%3D Occurrence Handle12668646
BP Guo JJ Mekalanos (2002) ArticleTitleRapid genetic analysis of Helicobacter pylori gastric mucosal colonization in suckling mice Proc Natl Acad Sci U S A 99 8354–9 10.1073/pnas.122244899 Occurrence Handle1:CAS:528:DC%2BD38XkvVGgu7g%3D Occurrence Handle12060779
S Suerbaum P Michetti (2002) ArticleTitleHelicobacter pylori infection N Engl J Med 347 1175–86 10.1056/NEJMra020542 Occurrence Handle1:CAS:528:DC%2BD38XnslShsbo%3D Occurrence Handle12374879
BJ Marshall JR Warren (1984) ArticleTitleUnidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration Lancet 1 1311–5 10.1016/S0140-6736(84)91816-6 Occurrence Handle1:STN:280:DyaL2c3hvVehtw%3D%3D Occurrence Handle6145023
ED Palmer (1954) ArticleTitleInvestigation of the gastric mucosal spirochetes of the human Gastroenterology 27 218–20 Occurrence Handle1:STN:280:DyaG2c7gtlCmtA%3D%3D Occurrence Handle13183283
G Bizzozero (1893) ArticleTitleUeber die schlauchformigen Dursen des Magen-darmkanals und die Beziehungen ihres Epithels zu dem Oberflachenepithel der Schleimhaut Arch Mikr Anat 42 82–152
K Kasai R Kobayashi (1919) ArticleTitleThe stomach spirochete occurring in mammals J Parasitol 6 1–10 10.2307/3271009
K Saito (2002) ArticleTitleIntroductory remark of Dr. Rokuzo Kobayashi’s achievements Keio J Med 51 2–3 Occurrence Handle12528927
BJ Marshall (2002) ArticleTitleGastric spirochaetes: 100 years of discovery before and after Kobayashi Keio J Med 51 33–7 Occurrence Handle12528934
DY Graham HM Malaty DG Evans DJ Evans SuffixJr PD Klein E Adam (1991) ArticleTitleEpidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status Gastroenterology 100 1495–501 Occurrence Handle1:STN:280:DyaK3M3gvFOjug%3D%3D Occurrence Handle2019355
J Parsonnet (1995) ArticleTitleThe incidence of Helicobacter pylori infection Aliment Pharmacol Ther 9 IssueIDSuppl 2 45–51 Occurrence Handle8547528
RW Frenck SuffixJr J Clemens (2003) ArticleTitleHelicobacter in the developing world Microbes Infect 5 705–13 10.1016/S1286-4579(03)00112-6 Occurrence Handle12814771
LE Hansson O Nyren AW Hsing R Bergstrom S Josefsson WH Chow et al. (1996) ArticleTitleThe risk of stomach cancer in patients with gastric or duodenal ulcer disease N Engl J Med 335 242–9 10.1056/NEJM199607253350404 Occurrence Handle1:STN:280:DyaK283ms1ertA%3D%3D Occurrence Handle8657240
E Zucca F Bertoni E Roggero G Bosshard G Cazzaniga E Pedrinis et al. (1998) ArticleTitleMolecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach N Engl J Med 338 804–10 10.1056/NEJM199803193381205 Occurrence Handle1:STN:280:DyaK1c7lvVSgtw%3D%3D Occurrence Handle9504941
W Fischbach B Dragosics ME Kolve-Goebeler C Ohmann A Greiner Q Yang et al. (2000) ArticleTitlePrimary gastric B-cell lymphoma: results of a prospective multicenter study. The German-Austrian Gastrointestinal Lymphoma Study Group Gastroenterology 119 1191–202 10.1053/gast.2000.19579 Occurrence Handle1:STN:280:DC%2BD3M%2Fkt1yltA%3D%3D Occurrence Handle11054376
AM Ekstrom M Held LE Hansson L Engstrand O Nyren (2001) ArticleTitleHelicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection Gastroenterology 121 784–91 10.1053/gast.2001.27999 Occurrence Handle1:STN:280:DC%2BD3MrlvFKmtQ%3D%3D Occurrence Handle11606491
M Naumann JE Crabtree (2004) ArticleTitleHelicobacter pylori-induced epithelial cell signalling in gastric carcinogenesis Trends Microbiol 12 29–36 10.1016/j.tim.2003.11.005 Occurrence Handle1:CAS:528:DC%2BD3sXhtVWjtLnK Occurrence Handle14700549
H Suzuki M Mori AA Sakaguchi M Suzuki S Miura H Ishii (1998) ArticleTitleEnhanced levels of C-X-C chemokine, human GROα, in H. pylori-associated gastric disease J Gastroenterol Hepatol 13 516–20 Occurrence Handle1:CAS:528:DyaK1cXktVCjt7k%3D Occurrence Handle9641651
M Karita MK Tummuru HP Wirth MJ Blaser (1996) ArticleTitleEffect of growth phase and acid shock on Helicobacter pylori cagA expression Infect Immun 64 4501–7 Occurrence Handle1:CAS:528:DyaK28XmsVWnsbc%3D Occurrence Handle8890198
JE Crabtree JI Wyatt GM Sobala G Miller DS Tompkins JN Primrose et al. (1993) ArticleTitleSystemic and mucosal humoral responses to Helicobacter pylori in gastric cancer Gut 34 1339–43 Occurrence Handle1:STN:280:DyaK2c%2FmtlGrsQ%3D%3D Occurrence Handle8244098
D Basso F Navaglia L Brigato MG Piva A Toma E Greco et al. (1998) ArticleTitleAnalysis of Helicobacter pylori vacA and cagA genotypes and serum antibody profile in benign and malignant gastroduodenal diseases Gut 43 182–6 Occurrence Handle1:STN:280:DyaK1M3gsFyguw%3D%3D Occurrence Handle10189841 Occurrence Handle10.1136/gut.43.2.182
JC Atherton P Cao RM Peek SuffixJr MK Tummuru MJ Blaser TL Cover (1995) ArticleTitleMosaicism in vacuolating cytotoxin alleles of Helicobacter pylori. Association of specific vacA types with cytotoxin production and peptic ulceration J Biol Chem 270 17771–7 10.1074/jbc.270.30.17771 Occurrence Handle1:CAS:528:DyaK2MXnt1Crt7Y%3D Occurrence Handle7629077
W Fischer J Puls R Buhrdorf B Gebert S Odenbreit R Haas (2001) ArticleTitleSystematic mutagenesis of the Helicobacter pylori cag pathogenicity island: essential genes for CagA translocation in host cells and induction of interleukin-8 Mol Microbiol 42 1337–48 10.1046/j.1365-2958.2001.02714.x Occurrence Handle1:CAS:528:DC%2BD3MXptFOiu70%3D Occurrence Handle11886563
M Stein R Rappuoli A Covacci (2000) ArticleTitleTyrosine phosphorylation of the Helicobacter pylori CagA antigen after cag-driven host cell translocation Proc Natl Acad Sci U S A 97 1263–8 10.1073/pnas.97.3.1263 Occurrence Handle1:CAS:528:DC%2BD3cXpvFeksg%3D%3D Occurrence Handle10655519
H Higashi R Tsutsumi S Muto T Sugiyama T Azuma M Asaka et al. (2002) ArticleTitleSHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein Science 295 683–6 10.1126/science.1067147 Occurrence Handle1:CAS:528:DC%2BD38XptF2rsQ%3D%3D Occurrence Handle11743164
M Selbach S Moese CR Hauck TF Meyer S Backert (2002) ArticleTitleSrc is the kinase of the Helicobacter pylori CagA protein in vitro and in vivo J Biol Chem 277 6775–8 10.1074/jbc.C100754200 Occurrence Handle1:CAS:528:DC%2BD38XitV2mtrg%3D Occurrence Handle11788577
J Tanaka T Suzuki H Mimuro C Sasakawa (2003) ArticleTitleStructural definition on the surface of Helicobacter pylori type IV secretion apparatus Cell Microbiol 5 395–404 10.1046/j.1462-5822.2003.00286.x Occurrence Handle1:CAS:528:DC%2BD3sXkvVeku7Y%3D Occurrence Handle12780777
R Tsutsumi H Higashi M Higuchi M Okada M Hatakeyama (2003) ArticleTitleAttenuation of Helicobacter pylori CagA × SHP-2 signaling by interaction between CagA and C-terminal Src kinase J Biol Chem 278 3664–70 10.1074/jbc.M208155200 Occurrence Handle1:CAS:528:DC%2BD3sXot1Krsw%3D%3D Occurrence Handle12446738
H Higashi R Tsutsumi A Fujita S Yamazaki M Asaka T Azuma et al. (2002) ArticleTitleBiological activity of the Helicobacter pylori virulence factor CagA is determined by variation in the tyrosine phosphorylation sites Proc Natl Acad Sci U S A 99 14428–33 10.1073/pnas.222375399 Occurrence Handle1:CAS:528:DC%2BD38XosF2hsrk%3D Occurrence Handle12391297
H Higashi A Nakaya R Tsutsumi K Yokoyama Y Fujii S Ishikawa et al. (2004) ArticleTitleHelicobacter pylori CagA induces Ras-independent morphogenetic response through SHP-2 recruitment and activation J Biol Chem 279 17205–16 10.1074/jbc.M309964200 Occurrence Handle1:CAS:528:DC%2BD2cXjt1Ggu74%3D Occurrence Handle14963045
UEH Mai GI Prez-Perez JB Allen SM Wahl MJ Blaser PD Smith (1992) ArticleTitleSurface proteins from Helicobacter pylori exhibit chemotactic activity for human leukocytes and are present in gastric mucosa J Exp Med 175 517–25 10.1084/jem.175.2.517 Occurrence Handle1:CAS:528:DyaK38XotFyktw%3D%3D Occurrence Handle1732414
PM Craig MC Territo WE Karnes JH Walsh (1992) ArticleTitleHelicobacter pylori secretes a chemotactic factor monocytes and neutrophils Gut 33 1020–3 Occurrence Handle1:STN:280:DyaK3s%2FhtlWguw%3D%3D Occurrence Handle1398224
M Suzuki S Miura M Suematsu D Fukumura I Kurose H Suzuki et al. (1992) ArticleTitleHelicobacter pylori-associated ammonia production enhances neutrophil-dependent gastric mucosal cell injury Am J Physiol 263 G719–25 Occurrence Handle1:CAS:528:DyaK3sXpvFaqsw%3D%3D Occurrence Handle1443147
MB Grisham MM Jefferson DF Melton EL Thomas (1984) ArticleTitleChlorination of endogenous amines by isolated neutrophils: ammonia-dependent bactericidal, cytotoxic, and cytolytic activities of the chloramines J Biol Chem 259 10404–13 Occurrence Handle1:CAS:528:DyaL2cXlt1yksb8%3D Occurrence Handle6381484
B Halliwell OI Aruoma (1991) ArticleTitleDNA damage by oxygen-derived species. Its mechanism and measurement in mammalian systems FEBS Lett 281 9–19 10.1016/0014-5793(91)80347-6 Occurrence Handle1:CAS:528:DyaK3MXisVaisbo%3D Occurrence Handle1849843
F Farinati R Cardin VM Russo G Busatto M Franco M Rugge (2003) ArticleTitleHelicobacter pylori CagA status, mucosal oxidative damage and gastritis phenotype: a potential pathway to cancer? Helicobacter 8 227–34 10.1046/j.1523-5378.2003.00149.x Occurrence Handle12752735
H Suzuki M Mori K Seto A Kai C Kawaguchi M Suzuki et al. (1999) ArticleTitleH. pylori-associated gastric pro- and anti-oxidant formation in Mongolian gerbils Free Radic Biol Med 26 679–84 10.1016/S0891-5849(98)00248-2 Occurrence Handle1:CAS:528:DyaK1MXitVKisbc%3D Occurrence Handle10218657
H Suzuki M Mori K Seto S Nagahashi C Kawaguchi A Kai et al. (1999) ArticleTitleEthanol intake preceding Helicobacter pylori inoculation promotes gastric mucosal inflammation in Mongolian gerbils J Gastroenterol Hepatol 14 1062–9 10.1046/j.1440-1746.1999.01999.x Occurrence Handle1:CAS:528:DC%2BD3cXmsVCltw%3D%3D Occurrence Handle10574132
H Suzuki T Masaoka H Hosoda T Ota Y Minegishi S Nomura et al. (2004) ArticleTitleHelicobacter pylori infection modifies gastric and plasma ghrelin dynamics in Mongolian gerbils Gut 53 187–94 10.1136/gut.2003.021568 Occurrence Handle1:CAS:528:DC%2BD2cXhs1Ght70%3D Occurrence Handle14724148
H Suzuki Y Minegishi Y Nomoto T Ota T Masaoka GR Brink Particlevan den et al. (2005) ArticleTitleDown-regulation of a morphogen (sonic hedgehog) gradient in the gastric epithelium of Helicobacter pylori-infected Mongolian gerbils J Pathol 206 186–97 10.1002/path.1763 Occurrence Handle1:CAS:528:DC%2BD2MXlsFejtbc%3D Occurrence Handle15818572
K Ogura S Maeda M Nakao T Watanabe M Tada T Kyutoku et al. (2000) ArticleTitleVirulence factors of Helicobacter pylori responsible for gastric diseases in Mongolian gerbil J Exp Med 192 1601–10 10.1084/jem.192.11.1601 Occurrence Handle1:CAS:528:DC%2BD3cXosF2ntrk%3D Occurrence Handle11104802
DA Israel N Salama CN Arnold SF Moss T Ando HP Wirth et al. (2001) ArticleTitleHelicobacter pylori strain-specific differences in genetic content, identified by microarray, influence host inflammatory responses J Clin Invest 107 611–20 10.1172/JCI11450 Occurrence Handle1:CAS:528:DC%2BD3MXhs12nsL4%3D Occurrence Handle11238562
H Suzuki T Masaoka H Hosoda S Nomura T Ohara K Kangawa et al. (2004) ArticleTitlePlasma ghrelin concentration correlates with the levels of serum pepsinogen I and pepsinogen I/II ratio—a possible novel and non-invasive marker for gastric atrophy Hepatogastroenterology 51 1249–54 Occurrence Handle1:CAS:528:DC%2BD2cXmvVGiu78%3D Occurrence Handle15362725
Nishizawa T, Suzuki H, Masaoka T, Minegishi Y, Iwasaki E, Hibi T. Helicobacter pylori eradication restored sonic hedgehog expression in the human stomach. Hepatogastroenterology 2007 (in press)
RMJ Peek SF Moss KT Tham GI Perez-Perez S Wang GG Miller et al. (1997) ArticleTitleHelicobacter pylori CagA+ strains and dissociation of gastric epithelial cell proliferation from apoptosis J Natl Cancer Inst 89 863–8 10.1093/jnci/89.12.863 Occurrence Handle1:CAS:528:DyaK2sXksVWqur0%3D Occurrence Handle9196252
H Suzuki M Miyazawa S Nagahashi K Seto A Kai M Suzuki et al. (2002) ArticleTitleAttenuated apoptosis in H. pylori-colonized gastric mucosa of Mongolian gerbils in comparison with mice Dig Dis Sci 47 90–9 10.1023/A:1013219621422 Occurrence Handle11837740
T Watanabe M Tada H Nagai S Sasaki M Nakao (1998) ArticleTitleHelicobacter pylori infection induces gastric cancer in Mongolian gerbils Gastroenterology 115 642–8 10.1016/S0016-5085(98)70143-X Occurrence Handle1:STN:280:DyaK1czoslynsA%3D%3D Occurrence Handle9721161
S Honda T Fujioka M Tokieda R Satoh A Nishizono M Nasu (1998) ArticleTitleDevelopment of Helicobacter pylori-induced gastric carcinoma in Mongolian gerbils Cancer Res 58 4255–9 Occurrence Handle1:CAS:528:DyaK1cXmsVyqs7Y%3D Occurrence Handle9766647
BJ Marshall DB McGechie PA Rogers RJ Glancy (1985) ArticleTitlePyloric Campylobacter infection and gastroduodenal disease Med J Aust 142 439–44 Occurrence Handle1:STN:280:DyaL2M7mtlWnug%3D%3D Occurrence Handle3982346
A Nomura GN Stemmermann PH Chyou GI Perez-Perez MJ Blaser (1994) ArticleTitleHelicobacter pylori infection and the risk for duodenal and gastric ulceration Ann Intern Med 120 977–81 Occurrence Handle1:STN:280:DyaK2c3ktFCqtQ%3D%3D Occurrence Handle7741826
EA Rauws GN Tytgat (1990) ArticleTitleCure of duodenal ulcer associated with eradication of Helicobacter pylori Lancet 335 1233–5 10.1016/0140-6736(90)91301-P Occurrence Handle1:STN:280:DyaK3c3lvVGnsw%3D%3D Occurrence Handle1971318
E Hentschel G Brandstatter B Dragosics AM Hirschl H Nemec K Schutze et al. (1993) ArticleTitleEffect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer N Engl J Med 328 308–12 10.1056/NEJM199302043280503 Occurrence Handle1:STN:280:DyaK3s7isFKhtw%3D%3D Occurrence Handle8419816
BJ Marshall CS Goodwin JR Warren R Murray ED Blincow SJ Blackbourn et al. (1988) ArticleTitleProspective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori Lancet 2 1437–42 10.1016/S0140-6736(88)90929-4 Occurrence Handle1:STN:280:DyaL1M%2FntVSiuw%3D%3D Occurrence Handle2904568
JG Penston (1994) ArticleTitleReview article: Helicobacter pylori eradication—understandable caution but no excuse for inertia Aliment Pharmacol Ther 8 369–89 Occurrence Handle1:STN:280:DyaK2M%2FnvVCjuw%3D%3D Occurrence Handle7986962 Occurrence Handle10.1111/j.1365-2036.1994.tb00304.x
GN Tytgat (1995) ArticleTitlePeptic ulcer and Helicobacter pylori: eradication and relapse Scand J Gastroenterol Suppl 210 70–2 Occurrence Handle1:STN:280:DyaK287hslyrug%3D%3D Occurrence Handle8578212
RJ Hopkins LS Girardi EA Turney (1996) ArticleTitleRelationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review Gastroenterology 110 1244–52 10.1053/gast.1996.v110.pm8613015 Occurrence Handle1:STN:280:DyaK287otlWlsQ%3D%3D Occurrence Handle8613015
L Laine RJ Hopkins LS Girardi (1998) ArticleTitleHas the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials Am J Gastroenterol 93 1409–15 Occurrence Handle1:STN:280:DyaK1cvgtFOmsQ%3D%3D Occurrence Handle9732917
AT Axon CA O’Morain KD Bardhan JP Crowe AD Beattie RP Thompson et al. (1997) ArticleTitleRandomised double blind controlled study of recurrence of gastric ulcer after treatment for eradication of Helicobacter pylori infection BMJ 314 565–8 Occurrence Handle1:STN:280:DyaK2s3gvVOksQ%3D%3D Occurrence Handle9055715
Y Fukuda I Yamamoto M Okui Y Tonokatsu K Tamura T Shimoyama (1995) ArticleTitleCombination therapy with mucosal protective agent for the eradication of Helicobacter pylori Eur J Gastroenterol Hepatol 7 IssueIDSuppl 1 S45–7 Occurrence Handle8574735
M Kato M Asaka M Kudo M Sukegawa M Katagiri T Koshiyama et al. (1996) ArticleTitleEffects of lansoprazole plus amoxycillin on the cure of Helicobacter pylori infection in Japanese peptic ulcer patients Aliment Pharmacol Ther 10 821–7 10.1046/j.1365-2036.1996.52194000.x Occurrence Handle1:CAS:528:DyaK28Xmslajsrs%3D Occurrence Handle8899093
M Lazzaroni M Perego S Bargiggia G Maconi R Fiocca E Solcia et al. (1997) ArticleTitleHelicobacter pylori eradication in the healing and recurrence of benign gastric ulcer: a two-year, double-blind, placebo controlled study Ital J Gastroenterol Hepatol 29 220–7 Occurrence Handle1:CAS:528:DyaK1cXnsVSiu7g%3D Occurrence Handle9646213
K Seppala P Pikkarainen P Sipponen E Kivilaakso MH Gormsen (1995) ArticleTitleCure of peptic gastric ulcer associated with eradication of Helicobacter pylori. Finnish Gastric Ulcer Study Group Gut 36 834–7 Occurrence Handle1:STN:280:DyaK2MzktVWrsw%3D%3D Occurrence Handle7615269
JJ Sung SC Chung TK Ling MY Yung VK Leung EK Ng et al. (1995) ArticleTitleAntibacterial treatment of gastric ulcers associated with Helicobacter pylori N Engl J Med 332 139–42 10.1056/NEJM199501193320302 Occurrence Handle1:STN:280:DyaK2M%2FpvVSrug%3D%3D Occurrence Handle7800005
Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev 2006 Apr 19;(2):CD003840
EJ Kuipers AS Pena G van Kamp AM Uyterlinde G Pals NF Pels et al. (1993) ArticleTitleSeroconversion for Helicobacter pylori Lancet 342 328–31 10.1016/0140-6736(93)91473-Y Occurrence Handle1:STN:280:DyaK3szivF2gtg%3D%3D Occurrence Handle8101585
R Roosendaal EJ Kuipers J Buitenwerf C Uffelen Particlevan SG Meuwissen GJ Kamp ParticleVan et al. (1997) ArticleTitleHelicobacter pylori and the birth cohort effect: evidence of a continuous decrease of infection rates in childhood Am J Gastroenterol 92 1480–2 Occurrence Handle1:STN:280:DyaK2svmtFertA%3D%3D Occurrence Handle9317067
JQ Huang S Sridhar RH Hunt (2002) ArticleTitleRole of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis Lancet 359 14–22 10.1016/S0140-6736(02)07273-2 Occurrence Handle1:CAS:528:DC%2BD38XmsV2msQ%3D%3D Occurrence Handle11809181
FK Chan KF To JC Wu MY Yung WK Leung T Kwok et al. (2002) ArticleTitleEradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial Lancet 359 9–13 10.1016/S0140-6736(02)07272-0 Occurrence Handle1:CAS:528:DC%2BD38XmsV2msA%3D%3D Occurrence Handle11809180
FK Chan SC Chung BY Suen YT Lee WK Leung VK Leung et al. (2001) ArticleTitlePreventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen N Engl J Med 344 967–73 10.1056/NEJM200103293441304 Occurrence Handle1:STN:280:DC%2BD3M7pvVKitw%3D%3D Occurrence Handle11274623
CJ Hawkey Z Tulassay L Szczepanski CJ Rensburg Particlevan A Filipowicz-Sosnowska A Lanas et al. (1998) ArticleTitleRandomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention Lancet 352 1016–21 10.1016/S0140-6736(98)04206-8 Occurrence Handle1:STN:280:DyaK1cvjtVGntg%3D%3D Occurrence Handle9759744
DA Drossman (2006) ArticleTitleThe functional gastrointestinal disorders and the Rome III process Gastroenterology 130 1377–90 10.1053/j.gastro.2006.03.008 Occurrence Handle16678553
J Tack NJ Talley M Camilleri G Holtmann P Hu JR Malagelada et al. (2006) ArticleTitleFunctional gastroduodenal disorders Gastroen terology 130 1466–79
H Suzuki T Nishizawa T Hibi (2006) ArticleTitleTherapeutic strategies for functional dyspepsia and the introduction of the Rome III classification J Gastroenterol 41 513–23 10.1007/s00535-006-1847-5 Occurrence Handle16868798
NJ Talley RH Hunt (1997) ArticleTitleWhat role does Helicobacter pylori play in dyspepsia and nonulcer dyspepsia? Arguments for and against H. pylori being associated with dyspeptic symptoms Gastroenterology 113 S67–77 10.1016/S0016-5085(97)70081-7 Occurrence Handle1:STN:280:DyaK1c%2Fls1OntA%3D%3D Occurrence Handle9394764
Moayyedi P, Soo S, Deeks J, Delaney B, Harris A, Innes M et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2005 Jan 25;(1):CD002096
N Chiba SJ Zanten ParticleVan P Sinclair RA Ferguson S Escobedo E Grace (2002) ArticleTitleTreating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial BMJ 324 1012–6 10.1136/bmj.324.7344.1012 Occurrence Handle1:CAS:528:DC%2BD38Xkt1aks7s%3D Occurrence Handle11976244
N Chiba SJ Veldhuyzen Van Zanten S Escobedo E Grace J Lee P Sinclair et al. (2004) ArticleTitleEconomic evaluation of Helicobacter pylori eradication in the CADET-Hp randomized controlled trial of H. pylori-positive primary care patients with uninvestigated dyspepsia Aliment Pharmacol Ther 19 349–58 10.1111/j.1365-2036.2004.01865.x Occurrence Handle1:STN:280:DC%2BD2c%2Fps1Gitw%3D%3D Occurrence Handle14984382
A Sonnenberg WF Townsend (1995) ArticleTitleCosts of duodenal ulcer therapy with antibiotics Arch Intern Med 155 922–8 10.1001/archinte.155.9.922 Occurrence Handle1:STN:280:DyaK2M3ktlOruw%3D%3D Occurrence Handle7726700
Delaney B, Ford AC, Forman D, Moayyedi P, Qume M. Initial management strategies for dyspepsia. Cochrane Database Syst Rev 2005 Oct 19;(4):CD001961
AC Ford M Qume P Moayyedi NL Arents AT Lassen RF Logan et al. (2005) ArticleTitleHelicobacter pylori “test and treat” or endoscopy for managing dyspepsia: an individual patient data meta-analysis Gastroenterology 128 1838–44 10.1053/j.gastro.2005.03.004 Occurrence Handle15940619
P Correa C Cuello E Duque (1976) ArticleTitleGastric cancer in Colombia. III. Natural history of precursor lesions J Natl Cancer Inst 57 1027–35 Occurrence Handle1:STN:280:DyaE2s%2FnsVeitA%3D%3D Occurrence Handle1003539
EJ Kuipers AM Uyterlinde AS Pena R Roosendaal G Pals GF Nelis et al. (1995) ArticleTitleLong-term sequelae of Helicobacter pylori gastritis Lancet 345 1525–8 10.1016/S0140-6736(95)91084-0 Occurrence Handle1:STN:280:DyaK2MzhtFGntw%3D%3D Occurrence Handle7791437
H Suzuki T Hibi (2006) ArticleTitleOxidative stress in Helicobacter pylori-associated gastroduodenal disease J Clin Biochem Nutr 39 56–63 10.3164/jcbn.39.56 Occurrence Handle1:CAS:528:DC%2BD28XhtVKitrrE
EM El-Omar M Carrington WH Chow KE McColl JH Bream HA Young et al. (2000) ArticleTitleInterleukin-1 polymorphisms associated with increased risk of gastric cancer Nature 404 398–402 10.1038/35006081 Occurrence Handle1:CAS:528:DC%2BD3cXitlyltb4%3D Occurrence Handle10746728
A Uehara T Okumura C Sekiya K Okamura Y Takasugi M Namiki (1989) ArticleTitleInterleukin-1 inhibits the secretion of gastric acid in rats: possible involvement of prostaglandin Biochem Biophys Res Commun 162 1578–84 10.1016/0006-291X(89)90855-3 Occurrence Handle1:CAS:528:DyaL1MXltlaht7k%3D Occurrence Handle2788416
IR Hwang T Kodama S Kikuchi K Sakai LE Peterson DY Graham et al. (2002) ArticleTitleEffect of interleukin 1 polymorphisms on gastric mucosal interleukin 1beta production in Helicobacter pylori infection Gastroenterology 123 1793–803 10.1053/gast.2002.37043 Occurrence Handle1:CAS:528:DC%2BD38Xps1yktb4%3D Occurrence Handle12454835
C Figueiredo JC Machado P Pharoah R Seruca S Sousa R Carvalho et al. (2002) ArticleTitleHelicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma J Natl Cancer Inst 94 1680–7 Occurrence Handle1:CAS:528:DC%2BD38Xpslequrw%3D Occurrence Handle12441323
R Rad C Prinz B Neu M Neuhofer M Zeitner P Voland et al. (2003) ArticleTitleSynergistic effect of Helicobacter pylori virulence factors and interleukin-1 polymorphisms for the development of severe histological changes in the gastric mucosa J Infect Dis 188 272–81 10.1086/376458 Occurrence Handle1:CAS:528:DC%2BD3sXmslShtb0%3D Occurrence Handle12854083
JC Machado C Figueiredo P Canedo P Pharoah R Carvalho S Nabais et al. (2003) ArticleTitleA proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma Gastroenterology 125 364–71 10.1016/S0016-5085(03)00899-0 Occurrence Handle1:CAS:528:DC%2BD3sXmvFygu70%3D Occurrence Handle12891537
P Sipponen M Kekki J Haapakoski T Ihamaki M Siurala (2985) ArticleTitleGastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data Int J Cancer 35 173–7 10.1002/ijc.2910350206
EJ Kuipers (1998) ArticleTitleReview article: relationship between Helicobacter pylori, atrophic gastritis and gastric cancer Aliment Pharmacol Ther 12 IssueIDSuppl 1 25–36 10.1111/j.1365-2036.1998.00009.x Occurrence Handle9701002
D Forman F Sitas DG Newell AR Stacey J Boreham R Peto et al. (1990) ArticleTitleGeographic association of Helicobacter pylori antibody prevalence and gastric cancer mortality in rural China Int J Cancer 46 608–11 10.1002/ijc.2910460410 Occurrence Handle1:STN:280:DyaK3M%2Fgsl2rsA%3D%3D Occurrence Handle2210881
InstitutionalAuthorNameThe EUROGAST Study Group (1993) ArticleTitleAn international association between Helicobacter pylori infection and gastric cancer Lancet 341 1359–62 10.1016/0140-6736(93)90938-D
InstitutionalAuthorNameIARC Working Group on the Evaluation of Carcinogenic Risks to Humans (1994) ArticleTitleSchistosomes, liver flukes and Helicobacter pylori IARC Monogr Eval Carcinog Risks Hum 61 177–240
A Ekstrom M Held L Hansson L Engstrand O Nyren (2001) ArticleTitleHelicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection Gastroenterology 121 784–91 10.1053/gast.2001.27999 Occurrence Handle1:STN:280:DC%2BD3MrlvFKmtQ%3D%3D Occurrence Handle11606491
G Rieder JL Merchant R Haas (2005) ArticleTitleHelicobacter pylori cag-type IV secretion system facilitates corpus colonization to induce precancerous conditions in Mongolian gerbils Gastroenterology 128 1229–42 10.1053/j.gastro.2005.02.064 Occurrence Handle1:CAS:528:DC%2BD2MXlt1Cisrg%3D Occurrence Handle15887107
EJ Kuipers GI Perez-Perez SG Meuwissen MJ Blaser (1995) ArticleTitleHelicobacter pylori and atrophic gastritis: importance of the cagA status J Natl Cancer Inst 87 1777–80 10.1093/jnci/87.23.1777 Occurrence Handle1:STN:280:DyaK28%2FnslSkuw%3D%3D Occurrence Handle7473834
J Parsonnet GD Friedman N Orentreich H Vogelman (1997) ArticleTitleRisk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection Gut 40 297–301 Occurrence Handle1:STN:280:DyaK2s3otFajtQ%3D%3D Occurrence Handle9135515
DM Parkin (2001) ArticleTitleGlobal cancer statistics in the year 2000 Lancet Oncol 2 533–43 10.1016/S1470-2045(01)00486-7 Occurrence Handle1:STN:280:DC%2BD387ntlCrtw%3D%3D Occurrence Handle11905707
EJ Kuipers GF Nelis EC Klinkenberg-Knol P Snel D Goldfain JJ Kolkman et al. (2004) ArticleTitleCure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial Gut 53 12–20 10.1136/gut.53.1.12 Occurrence Handle1:CAS:528:DC%2BD2cXptlKrtA%3D%3D Occurrence Handle14684569
WK Leung SR Lin JY Ching KF To EK Ng FK Chan et al. (2004) ArticleTitleFactors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication Gut 53 1244–9 10.1136/gut.2003.034629 Occurrence Handle1:STN:280:DC%2BD2cvgt1Cmuw%3D%3D Occurrence Handle15306578
C Ley A Mohar J Guarner R Herrera-Goepfert LS Figueroa D Halperin et al. (2004) ArticleTitleHelicobacter pylori eradication and gastric preneoplastic conditions: a randomized, double-blind, placebo-controlled trial Cancer Epidemiol Biomarkers Prev 13 4–10 10.1158/1055-9965.EPI-03-0124 Occurrence Handle1:CAS:528:DC%2BD2cXmsVWgtQ%3D%3D Occurrence Handle14744726
R Mera ET Fontham LE Bravo JC Bravo MB Piazuelo MC Camargo et al. (2004) ArticleTitleLong term follow up of patients treated for Helicobacter pylori infection Gut 54 1536–40 10.1136/gut.2005.072009
BE Schenk EJ Kuipers GF Nelis E Bloemena JC Thijs P Snel et al. (2000) ArticleTitleEffect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy Gut 46 615–21 10.1136/gut.46.5.615 Occurrence Handle1:CAS:528:DC%2BD3cXjsVShu7s%3D Occurrence Handle10764703
BC Wong SK Lam WM Wong JS Chen TT Zheng RE Feng et al. (2004) ArticleTitleHelicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial JAMA 291 187–94 10.1001/jama.291.2.187 Occurrence Handle1:CAS:528:DC%2BD2cXkvVCjuw%3D%3D Occurrence Handle14722144
S Take M Mizuno K Ishiki Y Nagahara T Yoshida K Yokota et al. (2005) ArticleTitleThe effect of eradicating Helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease Am J Gastroenterol 100 1037–42 10.1111/j.1572-0241.2005.41384.x Occurrence Handle15842576
H Yatsuya H Toyoshima A Tamakoshi S Kikuchi K Tamakoshi T Kondo et al. (2004) ArticleTitleIndividual and joint impact of family history and Helicobacter pylori infection on the risk of stomach cancer: a nested case-control study Br J Cancer 91 929–34 Occurrence Handle1:STN:280:DC%2BD2cvitF2rsA%3D%3D Occurrence Handle15280918
S Sasazuki M Inoue M Iwasaki T Otani S Yamamoto S Ikeda et al. (2006) ArticleTitleEffect of Helicobacter pylori infection combined with CagA and pepsinogen status on gastric cancer development among Japanese men and women: a nested case-control study Cancer Epidemiol Biomarkers Prev 15 1341–7 10.1158/1055-9965.EPI-05-0901 Occurrence Handle1:CAS:528:DC%2BD28XmslSgtLw%3D Occurrence Handle16835334
S Eidt M Stolte R Fischer (1994) ArticleTitleHelicobacter pylori gastritis and primary gastric non-Hodgkin’s lymphomas J Clin Pathol 47 436–9 Occurrence Handle1:STN:280:DyaK2c3pvFyrtA%3D%3D Occurrence Handle8027397
J Parsonnet S Hansen L Rodriguez AB Gelb RA Warnke E Jellum et al. (1994) ArticleTitleHelicobacter pylori infection and gastric lymphoma N Engl J Med 330 1267–71 10.1056/NEJM199405053301803 Occurrence Handle1:STN:280:DyaK2c7psFentg%3D%3D Occurrence Handle8145781
J Parsonnet PG Isaacson (2004) ArticleTitleBacterial infection and MALT lymphoma N Engl J Med 350 213–5 10.1056/NEJMp038200 Occurrence Handle1:CAS:528:DC%2BD2cXkvVKhsw%3D%3D Occurrence Handle14724298
A Mascarel Particlede A Ruskone-Fourmestraux A Lavergne-Slove F Megraud P Dubus JP Merlio (2005) ArticleTitleClinical, histological and molecular follow-up of 60 patients with gastric marginal zone lymphoma of mucosa-associated lymphoid tissue Virchows Arch 446 219–24 10.1007/s00428-005-1217-3 Occurrence Handle1:CAS:528:DC%2BD2MXis1OkurY%3D Occurrence Handle15742170
W Fischbach ME Goebeler-Kolve B Dragosics A Greiner M Stolte (2004) ArticleTitleLong term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series Gut 53 34–7 10.1136/gut.53.1.34 Occurrence Handle1:STN:280:DC%2BD2c%2FhtlegtQ%3D%3D Occurrence Handle14684573
S Nakamura T Matsumoto H Suekane H Matsumoto M Esaki T Yao et al. (2005) ArticleTitleLong-term clinical outcome of Helicobacter pylori eradication for gastric mucosa-associated lymphoid tissue lymphoma with a reference to second-line treatment Cancer 104 532–40 10.1002/cncr.21152 Occurrence Handle15937928
T Wundisch C Thiede A Morgner A Dempfle A Gunther H Liu et al. (2005) ArticleTitleLong-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication J Clin Oncol 23 8018–24 10.1200/JCO.2005.02.3903 Occurrence Handle16204012
M Raderer B Streubel S Woehrer A Puespoek U Jaeger M Formanek et al. (2005) ArticleTitleHigh relapse rate in patients with MALT lymphoma warrants lifelong follow-up Clin Cancer Res 11 3349–52 10.1158/1078-0432.CCR-04-2282 Occurrence Handle15867234
H Inagaki T Nakamura C Li T Sugiyama M Asaka J Kodaira et al. (2004) ArticleTitleGastric MALT lymphomas are divided into three groups based on responsiveness to Helicobacter Pylori eradication and detection of API2-MALT1 fusion Am J Surg Pathol 28 1560–7 10.1097/00000478-200412000-00003 Occurrence Handle15577674
H Liu H Ye A Ruskone-Fourmestraux D Jong ParticleDe S Pileri C Thiede et al. (2002) ArticleTitleT(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication Gastroenterology 122 1286–94 10.1053/gast.2002.33047 Occurrence Handle1:CAS:528:DC%2BD38Xkt1CrurY%3D Occurrence Handle11984515
BF Werdmuller RJ Loffeld (1997) ArticleTitleHelicobacter pylori infection has no role in the pathogenesis of reflux esophagitis Dig Dis Sci 42 103–5 10.1023/A:1018841222856 Occurrence Handle1:STN:280:DyaK2s7mt1WgtA%3D%3D Occurrence Handle9009123
CA Fallone AN Barkun MU Gottke LM Best VG Loo S Veldhuyzen van Zanten et al. (2000) ArticleTitleAssociation of Helicobacter pylori genotype with gastroesophageal reflux disease and other upper gastrointestinal diseases Am J Gastroenterol 95 659–69 10.1111/j.1572-0241.2000.01970.x Occurrence Handle1:STN:280:DC%2BD3c7ntlarug%3D%3D Occurrence Handle10710054
J Labenz AL Blum E Bayerdorffer (1997) ArticleTitleCuring Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis Gastroenterology 112 1442–7 10.1016/S0016-5085(97)70024-6 Occurrence Handle1:STN:280:DyaK2s3ot1Gisw%3D%3D Occurrence Handle9136820
N Vakil B Hahn D McSorley (2000) ArticleTitleRecurrent symptoms and gastro-oesophageal reflux disease in patients with duodenal ulcer treated for Helicobacter pylori infection Aliment Pharmacol Ther 14 45–51 10.1046/j.1365-2036.2000.00677.x Occurrence Handle1:STN:280:DC%2BD3c%2FpvVegtw%3D%3D Occurrence Handle10632644
W Schwizer M Thumshirn J Dent I Guldenschuh D Menne G Cathomas et al. (2001) ArticleTitleHelicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial Lancet 357 1738–42 10.1016/S0140-6736(00)04894-7 Occurrence Handle1:CAS:528:DC%2BD3MXkt1Khsro%3D Occurrence Handle11403809
H Suzuki T Masaoka S Nomura Y Hoshino K Kurabayashi Y Minegishi et al. (2003) ArticleTitleCurrent consensus on the diagnosis and treatment of H. pylori-associated gastroduodenal disease Keio J Med 52 163–73 Occurrence Handle14529149
JR Warren BJ Marshall (1983) ArticleTitleUnidentified curved bacilli on gastric epithelium in active chronic gastritis Lancet 1 IssueID8336 1273–5
BJ Marshall JR Warren GJ Francis SR Langton CS Goodwin B Chir et al. (1987) ArticleTitleRapid urease test in the management of Campylobacter pyloridis-associated gastritis Am J Gastroenterol 82 200–10 Occurrence Handle1:STN:280:DyaL2s7ltlartQ%3D%3D Occurrence Handle3548326
PD Klein HM Malaty RF Martin KS Graham RM Genta DY Graham (1996) ArticleTitleNoninvasive detection of Helicobacter pylori infection in clinical practice: the 13C urea breath test Am J Gastroenterol 91 690–4 Occurrence Handle1:STN:280:DyaK287os1KnsA%3D%3D Occurrence Handle8677930
C Wesjnen H Hendriks A Hoes W Verweij T Verheij N Wit Particlede (2001) ArticleTitleNew immunoassay for the detection of Helicobacter pylori infection compared with urease test, 13C test and histology: validation in the primary care setting J Microbiol Methods 46 235–40 10.1016/S0167-7012(01)00275-5
D Narinesingh T Ngo (2002) ArticleTitleImmunochromatographic flow-injection method for detection of human serum immunoglobulin G antibodies to Helicobacter pylori Ann Chim Acta 453 53–61 10.1016/S0003-2670(01)01486-6 Occurrence Handle1:CAS:528:DC%2BD38XptlCgtg%3D%3D
N Fujioka M Fahey G Hamada I Nishimoto L Kowalski K Iriya et al. (2001) ArticleTitleSerological Immunoglobulin G antibody titers to Helicobacter pylori in Japanese Brazilian and Non-Japanese Brazilian gastric cancer patients and controls in Sao Paulo Jpn J Cancer Res 92 829–35 Occurrence Handle1:CAS:528:DC%2BD3MXnsFSht7c%3D Occurrence Handle11509113
D Wu C Kuo C Lu Y Su F Yu Y Lee et al. (2001) ArticleTitleEvaluation of an office-based urine test for detecting Helicobacter pylori: a prospective pilot study Hepatogastroenterology 48 614–7 Occurrence Handle1:STN:280:DC%2BD38%2FitFOnsQ%3D%3D Occurrence Handle11462887
D Graham S Reddy (2001) ArticleTitleRapid detection of anti-Helicobacter pylori IgG in urine using immunochromatography Aliment Pharmacol Ther 15 699–702 10.1046/j.1365-2036.2001.00968.x Occurrence Handle1:CAS:528:DC%2BD3MXjslCjsb4%3D Occurrence Handle11328264
G Manes A Balzano G Iaquinto C Ricci M Piccirillo N Giardullo et al. (2001) ArticleTitleAccuracy of stool antigen test in posteradication assessment of Helicobacter pylori infection Dig Dis Sci 46 2440–4 10.1023/A:1012319718848 Occurrence Handle1:STN:280:DC%2BD3MnmvVGksg%3D%3D Occurrence Handle11713949
A Leodolter K Agha-Amiri U Peitz C Gerards M Ebert P Malfertheiner (2001) ArticleTitleValidity of a Helicobacter pylori stool antigen assay for the assessment of H. pylori status following eradication therapy Eur J Gastroenterol Hepatol 13 673–6 10.1097/00042737-200106000-00010 Occurrence Handle1:STN:280:DC%2BD38%2Fhs1WksA%3D%3D Occurrence Handle11434593
D Vaira N Vakil M Menegatti B Hoff Particlevan’t C Ricci L Gatta et al. (2002) ArticleTitleThe stool antigen test for detection of Helicobacter pylori after eradication therapy Ann Intern Med 136 280–7 Occurrence Handle1:CAS:528:DC%2BD38XhvF2ktL0%3D Occurrence Handle11848725
J Gisbert J Pajares (2001) ArticleTitleDiagnosis of Helicobacter pylori infection by stool antigen determination: a systematic review Am J Gastroenterol 96 2829–38 10.1111/j.1572-0241.2001.04235.x Occurrence Handle1:STN:280:DC%2BD3MnjvVWktA%3D%3D Occurrence Handle11693315
T Lind S Veldhuyzen van Zanten P Unge R Spiller E Bayerdorffer C O’Morain et al. (1996) ArticleTitleEradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study Helicobacter 1 138–44 Occurrence Handle1:STN:280:DyaK1c%2FmtFWnsA%3D%3D Occurrence Handle9398894
T Matsuhisa T Kawai T Masaoka H Suzuki M Ito Y Kawamura et al. (2006) ArticleTitleEfficacy of metronidazole as second-line drug for the treatment of Helicobacter pylori infection in the Japanese population: a multicenter study in the Tokyo Metropolitan Area Helicobacter 11 152–8 10.1111/j.1523-5378.2006.00394.x Occurrence Handle1:CAS:528:DC%2BD28XmtFamtLc%3D Occurrence Handle16684262
JP Gisbert M Castro-Fernandez F Bermejo A Perez-Aisa J Ducons M Fernandez-Bermejo et al. (2006) ArticleTitleThird-line rescue therapy with levofloxacin after two H. pylori treatment failures Am J Gastroenterol 101 243–7 10.1111/j.1572-0241.2006.00457.x Occurrence Handle1:CAS:528:DC%2BD28XitFSgsbY%3D Occurrence Handle16454825
T Nishizawa H Suzuki K Kurabayashi T Masaoka H Muraoka M Mori et al. (2006) ArticleTitleGatifloxacin resistance and mutations in gyra after unsuccessful Helicobacter pylori eradication in Japan Antimicrob Agents Chemother 50 1538–40 10.1128/AAC.50.4.1538-1540.2006 Occurrence Handle1:CAS:528:DC%2BD28XjvFOrsbg%3D Occurrence Handle16569878
Nishizawa T, Suzuki H, Umezawa A, Muraoka H, Iwasaki E, Masaoka T, et al. Rapid detection of point mutations conferring resistance to fluoroquinolone in gyr A of Helicobacter pylori by allele-specific polymerase chain reaction. J Clin Microbiol 2006; Nov.22; [Epub ahead of print]
WA Boer Particlede GN Tytgat (1995) ArticleTitleThe best therapy for Helicobacter pylori infection: should efficacy or side-effect profile determine our choice? Scand J Gastroenterol 30 401–7 Occurrence Handle7638563
LA Fischbach S Zanten Particlevan J Dickason (2004) ArticleTitleMeta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies Aliment Pharmacol Ther 20 1071–82 10.1111/j.1365-2036.2004.02248.x Occurrence Handle1:CAS:528:DC%2BD2MXmtVantQ%3D%3D Occurrence Handle15569109
N Sakaki (2003) ArticleTitleProblems occurring after Helicobacter pylori eradication and their countermeasures Nippon Rinsho 61 119–24 Occurrence Handle12607328
A Raghunath AP Hungin D Wooff S Childs (2003) ArticleTitlePrevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review BMJ 326 737 10.1136/bmj.326.7392.737 Occurrence Handle12676842
AS Raghunath AP Hungin D Wooff S Childs (2004) ArticleTitleSystematic review: the effect of Helicobacter pylori and its eradication on gastro-oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis Aliment Pharmacol Ther 20 733–44 10.1111/j.1365-2036.2004.02172.x Occurrence Handle1:STN:280:DC%2BD2cvmvFSjsw%3D%3D Occurrence Handle15379833
P Moayyedi R Feltbower J Brown S Mason J Mason J Nathan et al. (2000) ArticleTitleEffect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. Leeds HELP Study Group Lancet 355 1665–9 10.1016/S0140-6736(00)02236-4 Occurrence Handle1:STN:280:DC%2BD3czmtFWktw%3D%3D Occurrence Handle10905240
RF Harvey JA Lane LJ Murray IM Harvey JL Donovan P Nair (2004) ArticleTitleRandomised controlled trial of effects of Helicobacter pylori infection and its eradication on heartburn and gastro-oesophageal reflux: Bristol Helicobacter project BMJ 328 1417 10.1136/bmj.38082.626725.EE Occurrence Handle15126313
S Nomura H Esumi C Job SS Tan (1998) ArticleTitleLineage and clonal development of gastric glands Dev Biol 204 124–35 10.1006/dbio.1998.9055 Occurrence Handle1:CAS:528:DyaK1cXotFSjurY%3D Occurrence Handle9851847
JC Mills N Andersson CV Hong TS Stappenbeck JI Gordon (2002) ArticleTitleMolecular characterization of mouse gastric epithelial progenitor cells Proc Natl Acad Sci U S A 99 14819–24 10.1073/pnas.192574799 Occurrence Handle1:CAS:528:DC%2BD38Xpt1yrtrk%3D Occurrence Handle12409607
J Mahdavi B Sonden M Hurtig FO Olfat L Forsberg N Roche et al. (2002) ArticleTitleHelicobacter pylori SabA adhesin in persistent infection and chronic inflammation Science 297 573–8 10.1126/science.1069076 Occurrence Handle1:CAS:528:DC%2BD38XlslWku7s%3D Occurrence Handle12142529
DG Evans TK Karjalainen DJ Evans SuffixJr DY Graham CH Lee (1993) ArticleTitleCloning, nucleotide sequence, and expression of a gene encoding an adhesin subunit protein of Helicobacter pylori J Bacteriol 175 674–83 Occurrence Handle1:CAS:528:DyaK3sXkvVOqsb4%3D Occurrence Handle7678592
HJ Bennett IS Roberts (2005) ArticleTitleIdentification of a new sialic acid-binding protein in Helicobacter pylori FEMS Immunol Med Microbiol 44 163–9 10.1016/j.femsim.2004.11.008 Occurrence Handle1:CAS:528:DC%2BD2MXjslKgsLw%3D Occurrence Handle15866211
S Bury-Mone JM Thiberge M Contreras A Maitournam A Labigne H Reuse ParticleDe (2004) ArticleTitleResponsiveness to acidity via metal ion regulators mediates virulence in the gastric pathogen Helicobacter pylori Mol Microbiol 53 623–38 10.1111/j.1365-2958.2004.04137.x Occurrence Handle1:CAS:528:DC%2BD2cXmt1agsrc%3D Occurrence Handle15228539
JD Oh H Kling-Backhed M Giannakis LG Engstrand JI Gordon (2006) ArticleTitleInteractions between gastric epithelial stem cells and Helicobacter pylori in the setting of chronic atrophic gastritis Curr Opin Microbiol 9 21–7 10.1016/j.mib.2005.12.013 Occurrence Handle1:CAS:528:DC%2BD28XhtFSitbk%3D Occurrence Handle16406776
J Houghton C Stoicov S Nomura AB Rogers J Carlson H Li et al. (2004) ArticleTitleGastric cancer originating from bone marrow-derived cells Science 306 1568–71 10.1126/science.1099513 Occurrence Handle1:CAS:528:DC%2BD2cXhtVCisLbE Occurrence Handle15567866
H Suzuki BJ Marshall T Hibi (2006) ArticleTitleOverview: Helicobacter pylori and extragastric disease Int J Hematol 84 291–300 10.1532/IJH97.06180 Occurrence Handle1:CAS:528:DC%2BD2sXhvFKgtLo%3D Occurrence Handle17118754
D Veneri M Krampera M Franchini (2005) ArticleTitleHigh prevalence of sustained remission of idiopathic thrombocytopenic purpura after Helicobacter pylori eradication: a long-term follow-up study Platelets 16 117–9 10.1080/09537100400015153 Occurrence Handle1:CAS:528:DC%2BD2MXivF2isbk%3D Occurrence Handle15823868
D Veneri M Franchini M Krampera G Matteis Particlede P Solero G Pizzolo (2005) ArticleTitleAnalysis of HFE and TFR2 gene mutations in patients with acute leukemia Leuk Res 29 661–4 10.1016/j.leukres.2005.01.001 Occurrence Handle1:CAS:528:DC%2BD2MXjs1Klt74%3D Occurrence Handle15863206
T Inaba M Mizuno S Take K Suwaki T Honda K Kawai et al. (2005) ArticleTitleEradication of Helicobacter pylori increases platelet count in patients with idiopathic thrombocytopenic purpura in Japan Eur J Clin Invest 35 214–9 10.1111/j.1365-2362.2005.01471.x Occurrence Handle1:STN:280:DC%2BD2M7gtlGnsg%3D%3D Occurrence Handle15733077
M Konno S Muraoka M Takahashi T Imai (2000) ArticleTitleIron-deficiency anemia associated with Helicobacter pylori gastritis J Pediatr Gastroenterol Nutr 31 52–6 10.1097/00005176-200007000-00012 Occurrence Handle1:STN:280:DC%2BD3M7itFCmtw%3D%3D Occurrence Handle10896071
G Baysoy D Ertem E Ademoglu E Kotiloglu S Keskin E Pehlivanoglu (2004) ArticleTitleGastric histopathology, iron status and iron deficiency anemia in children with Helicobacter pylori infection J Pediatr Gastroenterol Nutr 38 146–51 10.1097/00005176-200402000-00008 Occurrence Handle1:CAS:528:DC%2BD2cXlvFWgug%3D%3D Occurrence Handle14734875
S Nahon P Lahmek J Massard B Lesgourgues N Mariaud de Serre L Traissac et al. (2003) ArticleTitleHelicobacter pylori-associated chronic gastritis and unexplained iron deficiency anemia: a reliable association? Helicobacter 8 573–7 10.1111/j.1523-5378.2003.00184.x Occurrence Handle14632670
YH Choe SK Kim YC Hong (2003) ArticleTitleThe relationship between Helicobacter pylori infection and iron deficiency: seroprevalence study in 937 pubescent children Arch Dis Child 88 178 10.1136/adc.88.2.178-a Occurrence Handle1:STN:280:DC%2BD3s%2FjtVGlsg%3D%3D Occurrence Handle12538339
B Annibale M Marignani B Monarca G Antonelli A Marcheggiano G Martino et al. (1999) ArticleTitleReversal of iron deficiency anemia after Helicobacter pylori eradication in patients with asymptomatic gastritis Ann Intern Med 131 668–72 Occurrence Handle1:STN:280:DyaK1Mvls1Cnuw%3D%3D Occurrence Handle10577329
M Marignani S Angeletti C Bordi F Malagnino C Mancino G Delle Fave et al. (1997) ArticleTitleReversal of long-standing iron deficiency anaemia after eradication of Helicobacter pylori infection Scand J Gastroenterol 32 617–22 Occurrence Handle1:STN:280:DyaK2szktlOktg%3D%3D Occurrence Handle9200297
M Kostaki S Fessatou T Karpathios (2003) ArticleTitleRefractory iron-deficiency anaemia due to silent Helicobacter pylori gastritis in children Eur J Pediatr 162 177–9 Occurrence Handle12655422
G Russo-Mancuso F Branciforte M Licciardello M La Spina (2003) ArticleTitleIron deficiency anemia as the only sign of infection with Helicobacter pylori: a report of 9 pediatric cases Int J Hematol 78 429–31 10.1007/BF02983815 Occurrence Handle1:CAS:528:DC%2BD2cXkslGmsw%3D%3D Occurrence Handle14704035
A Shiotani K Okada K Yanaoka H Itoh S Nishioka M Sakurane et al. (2001) ArticleTitleBeneficial effect of Helicobacter pylori eradication in dermatologic diseases Helicobacter 6 60–5 10.1046/j.1523-5378.2001.00009.x Occurrence Handle1:STN:280:DC%2BD3MvjsFGrsQ%3D%3D Occurrence Handle11328367
S Fukuda T Shimoyama N Umegaki T Mikami H Nakano A Munakata (2004) ArticleTitleEffect of Helicobacter pylori eradication in the treatment of Japanese patients with chronic idiopathic urticaria J Gastroenterol 39 827–30 10.1007/s00535-004-1397-7 Occurrence Handle15565400
DG Federman RS Kirsner JP Moriarty J Concato (2003) ArticleTitleThe effect of antibiotic therapy for patients infected with Helicobacter pylori who have chronic urticaria J Am Acad Dermatol 49 861–4 10.1016/S0190-9622(03)00846-6 Occurrence Handle14576665
Author information
Authors and Affiliations
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 2.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this licence, visit https://creativecommons.org/licenses/by-nc/2.0/.
About this article
Cite this article
Suzuki, H., Hibi, T. & Marshall, B. Helicobacter pylori: present status and future prospects in Japan. J Gastroenterol 42, 1–15 (2007). https://doi.org/10.1007/s00535-006-1990-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00535-006-1990-z